Rayner announces acquisition of Sophi

Posted on 16/01/2024

17/01/2024 | Rayner, a global leader in products for cataract surgery, headquartered in Worthing, UK, announces today that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines.

Throughout its 114-year history, Rayner has been at the forefront of innovation in ophthalmology and remains the only manufacturer of intraocular lenses in the UK. This acquisition marks a new chapter for the company as it branches out to include phaco technology as part of its extensive product portfolio.

Sophi (Swiss Ophthalmology Innovation) is an innovative phaco technology providing mobility, simplicity, and safety within the operating theatre. With advanced features including triple pump fluidics, active IOP control, clean venturi and day cassette, cable free power supply and wireless communication, Sophi presents a truly advanced surgical system.

Tim Clover, Rayner CEO, said: “The phaco machine plays a central role in cataract surgery. At Rayner we aspire to launch the highest quality products, inspired by surgeons and driven by science. Sophi shares this vision, and their machines are truly differentiated with breakthrough technology combined with stunning design which makes them such a good fit for Rayner. I’m excited about their product range today, as well as what we will be planning together for tomorrow.”

Thomas Koeppel, Founder and CEO of Sophi, commented: “Sophi was created by viewing things from a completely new perspective; to redefine the requirements of a perfect phaco system by focusing on the point of view of the surgeon and their team. We saw the same philosophy in Rayner and are excited to combine in order to offer Sophi through an expanded commercial team and to accelerate our innovation projects.”

The acquisition will enhance Rayner’s breadth of high-quality products for cataract surgery, enabling provision of a full offering also encompassing IOLs, OVDs, eye drops, pharmaceuticals, digital tools, and single-use recyclable instruments. As the newcomer to the Rayner product portfolio, Sophi comes highly regarded by medical professionals and is commended for its ease of use:

“Sophi has been my primary phaco machine for the last 3 years and I would highly recommend it to fellow high-volume premium cataract and refractive surgeons. I have found its superior fluidics, ease of use and in-field support from the manufacturer to be highly differentiated.” Erik L. Mertens,MD, FEBO, PCEO, FWCRS, Founder and Medical Director Medipolis Eye Centre.

The acquisition closed today, 17th January 2024.



About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley 1949, Rayner has the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.

Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions worldwide in over 80 countries through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.


Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.

©2024 Rayner Group, all rights reserved. ‘Rayner’ is a proprietary mark of the Rayner Group. All other trademarks are property of their respective owners.

Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ | EC-2023-192

Share this article